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Objectives: Although lymphatic spread is common in intrahepatic cholangiocarcinoma (ICC), lym-
phadenectomy is not widely performed as part of operative resection in this disease. The objectives of
this study were to assess national trends for lymphadenectomy and its impact on survival in patients with
ICC.
Methods: The National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) registry
was queried to identify patients with ICC (n = 4893) reported during 1988–2007. Kaplan–Maier and Cox
proportional hazards regression were used to analyse survival.
Results: Five-year overall survival (OS) was 5.2%. Lymph node (LN) status was available for 48.9%
(n = 2391) of patients. Histologic LN evaluation was performed in 13.5% (n = 658) of patients for a median
of two (interquartile range: 1–3) LNs. During the study period, the frequency of histologic LN assessment
(P = 0.78) did not change in liver resection patients. In the 733 resected patients, positive vs. negative LN
status was associated with worse 5-year OS of 8.4% vs. 25.9%, respectively (hazard ratio = 1.8;
P < 0.001).
Conclusions: Nodal status is an important prognostic factor for survival in patients diagnosed with ICC.
In the USA, few patients undergo hepatic resection with lymphadenectomy; therefore, the clinical benefit
of formal lymphadenectomy in ICC remains unknown.
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Introduction
Intrahepatic cholangiocarcinoma (ICC) is the second most
common primary hepatic malignancy worldwide.1 The incidence
of ICC in the USA has increased over the last two decades by
165%.2–5 Despite advances in hepatic resection techniques and
decreased perioperative mortality, 5-year overall survival (OS) in
resected ICC patients is only 15–40%.6,7 Surgical resection cur-
rently represents the only hope of cure. Because of the rarity of the
disease, as well as the limitations of single-institution studies, the
optimal treatment strategy for ICC has yet to be defined.
The anatomic classification of ICC includes ‘peripheral’ cholan-
giocarcinoma and is considered to be distinct from extrahepatic
cholangiocarcinoma (ECC), which includes Klatskin (hilar)
tumours located at the bile duct bifurcation and more ‘distal’ bile
duct cancers. Unfortunately, the lack of a consistent anatomic
classification scheme and the frequent inclusion of hilar cholan-
giocarcinoma and gallbladder cancer have complicated the
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interpretation of existing studies of surgical interventions in
ICC.5,8 This discrepancy was addressed in the 7th edition of the
American Joint Committee on Cancer (AJCC) Staging Manual.9,10
The revised tumour–node–metastasis (TNM) staging system pro-
posed by Nathan et al.9 places more emphasis on the extent of
invasion than on tumour size. Importantly, lymph node (LN)
involvement is a key feature of the AJCC staging scheme.
Despite the known predilection of this malignancy to spread
to local LNs, lymphadenectomy is not a widely performed com-
ponent of surgical resection for ICC in Western medical centres.
The rarity of resectable ICC and the inadequacies of the findings
of under-powered, single-institution studies have limited the
ability to assess the utility of lymphadenectomy. The aim of this
study was to utilize the US National Cancer Institute (NCI) Sur-
veillance, Epidemiology and End Results (SEER) database
(http://seer.cancer.gov) to characterize national trends in LN
evaluation in unresectable and resectable patients with ICC. In
addition, the survival of patients with ICC based on LN status
was evaluated.
Materials and methods
This is a retrospective Mayo Clinic Institutional Review Board-
approved cohort study using the SEER cancer registry database.
The NCI SEER programme produces a public-use database rep-
resenting 17 population-based cancer registries.11 The 1973–2007
SEER database contains cancer-specific data on incidence rates,
individual patient and tumour characteristics, treatment and
follow-up survival rates. Previous studies of ICC have utilized the
SEER database to establish the AJCC staging system, assess the
survival benefit of surgical resection and adjuvant radiation
therapy, and describe the incidence of ICC over the last three
decades.2,9,12–14 The SEER database was accessed remotely using the
NCI surveillance research software SEER*Stat Version 6.6.2
(http://seer.cancer.gov/seerstat), following authorization from the
NCI in August 2010.
Subject identification
The study group was limited to patients reported during 1988–
2007 because details on regional LN sampling or dissection were
not collected prior to 1988. The study group was derived from 15
registries within the SEER programme and excluded the Rural
Georgia and the Alaska Native Tumor Registries, which each
reported fewer than 15 patients diagnosed with ICC during this
time interval. Patients in Louisiana during July–December 2005
were not included because of disruption caused by hurricane
Katrina. Using the International Classification of Diseases for
Oncology (3rd edition, ICD-O-3) topography code for liver
(22.0), combined with the histology code for cholangiocarcinoma
(8160), and the topography code for intrahepatic bile duct (22.1),
combined with histology codes for malignant neoplasm (8000),
malignant tumour cells (8001), carcinoma (8010), undifferenti-
ated carcinoma (8020), adenocarcinoma (8140), and cholangio-
carcinoma (8160), 6650 patients with ICC were identified.15
Specific exclusion criteria were then applied to ensure the iden-
tification of ICC patients. Exclusion criteria included: diagnosis at
death or on the birth certificate; hilar and extrahepatic cholang-
iocarcinoma; gallbladder cholangiocarcinoma; hepatocellular car-
cinoma; metastatic adenocarcinoma (e.g. pancreatic cancer);
treatment with liver transplant, and age of <18 years. Five patients
with no evidence of malignancy (T0) on final pathology were
excluded. Further exclusion criteria included: diagnosis by clinical
diagnosis only without confirmatory tissue diagnosis; diagnosis
based on direct visualization without microscopic confirmation;
diagnosis based on only positive laboratory tests or markers, and
diagnosis by radiographic images only without microscopic con-
firmation. Using the above selection criteria, 4893 patients were
identified with histology of cholangiocarcinoma (n = 4166,
85.1%), bile duct adenocarcinoma (n = 631, 12.9%), bile duct
carcinoma (n = 68, 1.4%), malignant neoplasm of the bile duct
(n = 18, 0.4%), malignant tumour cells of the bile duct (n = 8,
0.2%), and undifferentiated bile duct carcinoma (n = 2, 0.04%).
Identification of procedural codes
Site-specific surgery codes for ICC used in the SEER database
have changed several times over the last 30 years. Factoring
changes in surgery codes, site-specific surgery was recoded into
more general categories of: no surgical procedure (n = 3303,
67.5%); biopsy only (n = 654, 13.4%); limited surgical therapy
(n = 81, 1.7%); wedge resection, segmental resection, simple
excision of tumour (n = 279, 5.7%); lobectomy, extended lobec-
tomy, hepatectomy, with or without lymphadenectomy, with or
without bile duct resection (n = 454, 9.3%); not otherwise speci-
fied (NOS) (n = 87, 1.8%), and missing (n = 35, 0.7%). A sub-
group, ‘major liver resection’ (n = 733, 15.0%), consisted of
patients treated with wedge resection, segmental resection,
simple excision of tumour, lobectomy, extended lobectomy or
hepatectomy. Liver biopsy and tumour ablation were not con-
sidered major liver resections.
American Joint Committee on Cancer staging
Staging for patients reported during 2004–2007 was reported
according to the AJCC Staging Manual, 6th edition.16 In order to
establish tumour stage for all study patients, extent of disease
(EoD) and collaborative staging (CS) codes provided by SEER
were used to derive each patient’s overall stage and individual T, N
and M classifications according to the AJCC Staging Manual, 7th
edition.10 The new AJCC, 7th edition T-classification scheme
emphasizes tumour invasion and growth pattern rather than size;
as the SEER registry did not code periductal invasion, it was not
possible to assign patients with a T4 designation or use T4 to
derive stage IVa disease. Therefore, stage IVa disease was defined as
any T-stage and evidence of regional LN metastasis.
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Lymph node assessment
The SEER database provides a detailed record of regional LN
evaluation after 1988, including type of LN evaluation (e.g. aspi-
ration), number of regional nodes examined and number of his-
tologically positive regional nodes. During 1988–2003, specific LN
regions were coded; however, during 2004–2007, these data were
consolidated into data on regional or distant LNs, which prevents
analysis based on the site or location of LNs evaluated. The SEER
registry used EoD (1988–2003) and CS (2004–2007) codes to
document LN involvement based on clinical and pathology
records. These codes were used to define AJCC 7th edition
N-stage. Regional LN evaluation and positive or negative status
were based on pathology reports only and required histologic
confirmation. A subgroup (n = 658, 13.5%) of patients, ‘lymph
nodes evaluated’, was defined using the code for ‘regional nodes
examined’ provided by SEER. Lymph nodes evaluated by aspira-
tion (n = 15, 0.3%) were included in this subgroup.
Follow-up and survival
The date of last follow-up (collected annually) was defined as the
last date the patient was actually seen by a physician or contacted
by the hospital registry, or as the date of death. Overall survival
time was calculated using the date of death, last date known to be
alive or the follow-up cut-off date for the dataset (November
2009). If a patient had died within 1 month of diagnosis, survival
time was coded as 0.1 month to avoid a time bias in survival (n =
406, 8.3%). Because estimates of overall and disease-specific sur-
vival for the entire study group were similar, only OS is reported.
Statistical analysis
Statistical analyses were performed using sas Version 9.2 (SAS
Institute, Inc., Cary, NC, USA). Analyses were performed for the
entire cohort (n = 4893), as well as for subgroups of patients
who underwent major liver resection (n = 733) and patients in
whom LNs were evaluated (n = 658). To verify the recoding
schemes and completeness of the dataset, additional subgroup
analyses were performed by registry and for time intervals in
which SEER made major changes in coding definitions (1988–
1997, 1998–2003, 2004–2007). Variables in the analyses included
age, sex, race, diagnosis year, registry, histology, grade, AJCC
7th edition stage, TNM classification, tumour size, number of
regional LNs evaluated, number of positive regional LNs, radia-
tion treatment, cancer-directed surgery (as defined by SEER),
and site-specific surgery.
Descriptive statistics are reported for all study variables as the
median with interquartile range (IQR) or the count with percent-
age, as appropriate. The association of metastatic disease docu-
mentation (M0, M1, unknown) and LN status (N0, N1, unknown)
was assessed using the chi-squared test. Linear regression was used
to assess the association between diagnosis year and the number of
LNs evaluated. Univariate and multivariable survival analyses were
performed using Cox proportional hazards regression. Survival
was assessed in three patient cohorts comprising: all patients; the
subset of patients who underwent evaluation of at least one LN,and
the subset of patients who underwent major liver resection. Mul-
tivariable models were developed based on a univariate overall
P-value of <0.05 and missing data of <10% (Table 1). The back-
ward selection method was used to identify variables indepen-
dently associated with survival. Those variables considered for the
subgroup multivariable models were age, diagnosis year, radiation,
AJCC 7th edition TNM classification, and major liver resection.
Proportional hazards assumptions were investigated. Univariate
logistic regression was used to identify factors associated with
undergoing LN evaluation. All tests with a P-value of <0.05 were
accepted as indicating statistical significance.
Table 1 Intrahepatic cholangiocarcinoma patient characteristics
(n = 4893)
Variable Missing,
n (%)
Male sex, n (%) 2539 (51.9) 0 (0)
White race, n (%) 3936 (80.6) 9 (0.2)
Age, years, median (IQR) 68 (57–76) 0 (0)
Diagnosis year, n (%) 0 (0)
1988–1997 1265 (25.8)
1998–2003 1913 (39.1)
2004–2007 1715 (35.1)
Grade, n (%) 2778 (56.8)
Well differentiated 308 (14.6)
Moderately differentiated 863 (40.8)
Poorly differentiated 890 (42.1)
Undifferentiated 54 (2.6)
Tumour size, cm, median (IQR) 6.0 (3.8–9.0) 2865 (58.6)
AJCC 7th edn stage, n (%) 901 (18.4)
Stage I 939 (23.5)
Stage II 142 (3.6)
Stage III 712 (17.8)
Stage IV 2199 (55.1)
T-stage, n (%) 1788 (36.5)
T1 1053 (33.9)
T2a 171 (5.5)
T2b 877 (28.2)
T3 1004 (32.3)
T4 a
N-stage (N0), n (%) 1788 (74.8) 2503 (51.1)
M-stage (M0), n (%) 2632 (64.2) 792 (16.2)
Histologic regional LN evaluation, n (%) 658 (13.5) 185 (3.8)
Radiation therapy, n (%) 767 (16.0) 89 (1.8)
Major liver resection, n (%) 733 (15.1) 35 (0.7)
aThe AJCC Staging Manual, 7th edition, defines T4 as tumour with
periductal invasion. Cases in the SEER registry did not document peri-
ductal invasion and therefore no T4 cases were recorded.
IQR, interquartile range; AJCC, American Joint Committee on Cancer;
LN, lymph node.
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Results
Patient characteristics
Of the 6650 patients identified in the SEER registry for 1988–
2007, 4893 (73.6%) were eligible for inclusion in this study.
Patient and tumour characteristics are outlined in Table 1.
Lymph node evaluation
Clinical LN status (N0 and N1) was available for 2391 (48.9%)
patients. Major liver resection was performed in 733 (15.0%)
patients, of whom 361 (49.3%) patients underwent histologic LN
evaluation. Histologic status (positive or negative) of regional LNs
was documented in 658 (13.5%) patients. Regional LNs were not
evaluated in 4050 (82.8%) patients and LN evaluation data were
missing in 185 (3.8%) patients.
Evidence of distant disease was significantly associated with
documentation of N-stage (P < 0.001). N-stage was documented
in 1798 of 2632 (68.3%) patients with no evidence of metastatic
disease (M0) and 556 of 1470 (37.8%) patients with metastatic
disease (M1).
Of the 658 patients in whom LN evaluation was conducted, the
number of nodes evaluated was documented in 529 (80.4%) cases.
The number of LNs examined changed over time (P < 0.001) from
a median of one LN (IQR: 1–3) in 1988–1997 to two LNs (IQR:
1–4) in 2004–2007. In 15 (2.3%) patients, LNs were evaluated by
fine needle aspiration alone. Data on nodal status were missing for
one (0.2%) patient. The median number of LNs examined was
two (IQR: 1–3) in the entire cohort, two (IQR: 1–4) in liver resec-
tion patients, and one (IQR: 1–2) in non-liver resection patients.
One LN was evaluated in 248 (46.9%) patients, two LNs in 91
(17.2%) patients, five LNs in 27 (5.1%) and over 10 LNs in only 32
(6.1%) patients.
Positive LNs were confirmed in 317 patients (48.2% of those
evaluated) at a median of one positive node (IQR: 1–2). Of
patients for whom the number of positive nodes was documented
(n = 244), 163 (66.8%) had one positive node, 40 (16.4%) had two
positive nodes, 28 (11.5%) had three or four positive nodes, 10
(4.1%) had five to nine positive nodes and only three (1.2%) had
10 or more positive nodes.
Factors associated with LN evaluation
Factors associated with performing LN evaluation were assessed
with univariate logistic regression (Table 2). Histologic LN status
was documented in 19.1% of patients with M0 disease and
10.0% of M1 patients. A patient with M1 status was 0.5 times as
likely as an M0 patient to undergo LN evaluation (P < 0.001).
Among all patients, the median age of those who underwent
regional LN evaluation was significantly lower than that of those
who did not (62 years vs. 69 years; odds ratio [OR] = 0.7
per 10 years; P < 0.001). Increased tumour size was associated
with decreased odds of LN evaluation, but this difference was
not clinically significant (OR = 0.97 per 1 cm; P = 0.014).
Later year of diagnosis was associated with decreased odds
of LN evaluation, but this difference was also not clinically sig-
nificant (OR = 0.98 per 1 year; P = 0.014). At least one LN was
evaluated in 188 (15.5%) patients during 1988–1997, 241
(13.1%) patients during 1998–2003, and 229 (13.8%) patients
during 2004–2007.
Significant variation in the percentages of patients undergoing
regional LN evaluation was noted between registries, with the
highest observed percentage (24.8%) in the Atlanta registry and
the lowest (10.9%) in the Connecticut registry (P = 0.003). Los
Angeles was chosen as the reference registry as it contributed the
highest number of patients. Most registries had an OR close to 1.0
(similar odds of having LNs evaluated). Registries in which the
odds of LN evaluations were significantly increased were those in
Atlanta (OR = 2.3, 95% confidence interval [CI] 1.5–3.5) and
Kentucky (OR = 1.7, 95% CI 1.1–2.7).
In patients treated with liver resection, age was associated with
LN assessment (OR = 0.7 per 10 years; P < 0.001). Tumour size
(P = 0.987), year of diagnosis (P = 0.780) and reporting registry
(P = 0.734) were not associated with performance of a lym-
phadenectomy in patients treated with major liver resection.
Table 2 Univariate analysis of factors associated with lymph node evaluation in patients with intrahepatic cholangiocarcinoma
All patients (n = 4893) Major liver resection (n = 733)
OR 95% CI P-value OR 95% CI P-value
Agea 0.71 (0.67–0.76) <0.001 0.71 (0.63–0.80) <0.001
White race 1.31 (1.05–1.64) 0.018 1.28 (0.88–1.88) 0.197
Female 1.05 (0.89–1.24) 0.572 0.88 (0.66–1.18) 0.390
Tumour size 0.97 (0.94–0.99) 0.014 1.00 (0.96–1.05) 0.987
AJCC 7th edition M1 0.48 (0.39–0.58) <0.001 0.87 (0.53–1.43) 0.587
Diagnosis yearb 0.98 (0.96–1.00) 0.014 1.00 (0.97–1.04) 0.780
Major liver resection 12.68 (10.50–15.31) <0.001 – – –
aOdds ratio per 10-year increment.
bModelled as a continuous variable.
OR, odds ratio; 95% CI, 95% confidence interval; AJCC, American Joint Committee on Cancer.
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Survival analysis
Overall 5-year survival was 5.2% and disease-specific 5-year sur-
vival was 7.5% for all study patients. Clinical characteristics
potentially associated with survival in all patients and in the sub-
groups of LN evaluation patients and major liver resection
patients are summarized in Table 3.
Both AJCC 7th edition clinical N-stage (Fig. 1A) and histologic
LN status (Fig. 2A) were associated with survival for all ICC
patients. Five-year OS was worse in N1 patients compared with
N0 patients, at 2.3% vs. 9.8%, respectively (N1 hazard ratio [HR]
= 1.3; P < 0.001). Five-year OS was worse in histologically node-
positive patients compared with node-negative patients, at 3.7%
Table 3 Univariate survival analysis for all patients and subgroups
All patients (n = 4893) Major liver resection (n = 733) Lymph nodes evaluated (n = 658)
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Agea 1.2 1.1–1.2 <0.001 1.1 1.0–1.2 0.022 1.1 1.0–1.2 0.001
Male sex 1.1 1.0–1.2 0.002 1.1 0.9–1.3 0.550 1.1 1.0–1.3 0.176
Diagnosis yearb 1.0 1.0–1.0 <0.001 1.0 0.9–1.0 <0.001 1.0 0.9–1.0 <0.001
Non-White race 1.1 1.0–1.1 0.253 1.0 0.8–1.2 0.818 1.2 1.0–1.5 0.084
Grade
Well differentiated 1.0 – Ref 1.0 – Ref 1.0 – Ref
Moderately differentiated 1.1 1.0–1.3 0.100 1.3 1.0–1.9 0.087 1.3 1.0–1.9 0.101
Poorly differentiated 1.6 1.4–1.8 <0.001 1.9 1.3–2.6 <0.001 2.0 1.4–2.8 <0.001
Undifferentiated 2.1 1.5–2.8 <0.001 2.4 1.1–5.1 0.023 2.4 1.0–5.2 0.037
Regional lymph node status
Negative 1.0 – Ref 1.0 – Ref 1.0 – Ref
Positive 1.8 1.5–2.1 <0.001 1.8 1.4–2.4 <0.001 1.9 1.6–2.3 <0.001
Unknown 2.3 2.1–2.7 <0.001 1.1 0.9–1.3 0.433 – – –
Radiation therapy 0.7 0.7–0.8 <0.001 1.1 0.9–1.4 0.253 0.9 0.7–1.0 0.115
Major liver resection 0.3 0.3–0.4 <0.001 – – – 0.4 0.3–0.5 <0.001
Tumour size (cm) 1.0 1.0–1.0 0.004 1.0 1.0–1.1 0.018 1.0 1.0–1.1 0.015
AJCC 7th edition stage
Stage I 1.0 – Ref 1.0 – Ref 1.0 – Ref
Stage II 0.9 0.7–1.1 0.169 1.7 1.2–2.5 0.005 1.4 0.8–2.4 0.296
Stage III 1.6 1.4–1.7 <0.001 1.9 1.4–2.5 <0.001 1.5 1.0–2.3 0.046
Stage IVa 1.3 1.2–1.5 <0.001 2.7 2.1–3.4 <0.001 2.5 1.9–3.3 <0.001
Stage IVb 2.4 2.2–2.7 <0.001 4.3 3.0–6.1 <0.001 5.5 4.0–7.6 <0.001
AJCC 7th edition T-stagec
T1 1.0 – Ref 1.0 – Ref 1.0 – Ref
T2a 0.9 0.7–1.0 0.091 1.7 1.2–2.3 0.004 1.3 0.9–2.1 0.167
T2b 1.5 1.4–1.7 <0.001 2.0 1.5–2.7 <0.001 1.8 1.4–2.5 <0.001
T3 1.4 1.3–1.5 <0.001 2.6 2.1–3.3 <0.001 2.2 1.7–2.8 <0.001
AJCC 7th edition N-stage
N0 1.0 – Ref 1.0 – Ref 1.0 – Ref
N1 1.3 1.2–1.4 <0.001 2.0 1.6–2.5 <0.001 1.9 1.6–2.3 <0.001
Unknown N-stage 1.7 1.6–1.8 <0.001 1.6 1.3–2.0 <0.001 – – –
AJCC 7th edition M-stage
M0 1.0 – Ref 1.0 – Ref 1.0 – Ref
M1 2.0 1.8–2.1 <0.001 2.5 1.9–3.3 <0.001 2.6 2.2–3.2 <0.001
aAge in 10-year increments.
bModelled as a continuous variable.
cThe AJCC Staging Manual, 7th edition, defines T4 as tumour with periductal invasion. Cases in the SEER registry do not document periductal
invasion and therefore no T4 cases were recorded.
95% CI, 95% confidence interval; HR, hazard ratio; AJCC, American Joint Committee on Cancer.
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vs. 19.3%, respectively (node-positive HR = 1.8; P < 0.001). In
patients with unknown clinical N-stage, 5-year OS was 2.8%.
Five-year OS in patients with unknown histologic LN status was
4.1%. After controlling for age, race, sex, SEER registry and history
of major liver resection, performance of a histologic LN evalua-
tion was not an independent predictor of survival (P = 0.138).
In the 733 resected patients, N-stage (Fig. 1B) and positive LN
status (Fig. 2B) were associated with survival. Five-year OS in
resected patients was 23.0%. In this subgroup, 5-year OS was
worse in N1 patients compared with N0 patients, at 7.3% vs.
28.4%, respectively (N1 HR = 2.0; P < 0.001). Five-year OS was
(A)
(B)
Figure 1 Kaplan–Meier survival by clinical N-stage in (A) all patients
with intrahepatic cholangiocarcinoma (ICC; n = 4893) and (B)
patients with ICC treated with major liver resection (n = 733)
(A)
(B)
Figure 2 Kaplan–Meier survival curves by histologic lymph node
status in (A) all patients with intrahepatic cholangiocarcinoma (ICC;
n = 4707; missing data lymph node status data, n = 186) and (B)
patients with ICC treated with major liver resection (n = 719; missing
lymph node status data, n = 14)
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worse in histologically node-positive patients compared with
node-negative patients, at 8.4% vs. 25.9%, respectively (node-
positive HR = 1.8; P < 0.001). Five-year OS was similar in node-
negative patients and patients with unknown regional node status
(25.9% vs. 26.8%; P = 0.433).
In a subgroup analysis of 658 ICC patients in whom histologic
regional LN evaluation was performed, 5-year OS was 11.7%.
Positive LN status resulted in a 5-year OS of 3.7% compared
with 19.3% in node-negative patients (node-positive HR = 1.9;
P < 0.001) (Fig. 3).
Given the significant association between LN status and sur-
vival, the impact of the number of positive LNs on survival in
patients who underwent major liver resection was evaluated. For
each additional positive LN, the risk for death increased slightly
(HR = 1.2 per positive LN, 95% CI 1.1–1.4; P < 0.001). Because
evaluations of more than two LNs were uncommon, further
analyses of survival based on the extent of LN dissection or LN
ratio were not performed.
Multivariable Cox regression survival analyses were performed
to evaluate the significance of regional LN metastasis for survival
in ICC patients treated with major liver resection and patients
who underwent histologic LN evaluation. Separate models with
N-stage and histologic LN status (positive, negative, unknown)
were developed, given their collinearity. Entry variables into the
multivariable model included age, diagnosis year, liver resection,
T-stage and M-stage. For patients treated with major liver resec-
tion, both N1 stage (HR = 1.7, 95% CI 1.3–2.2; P < 0.001) and
histologically positive regional LN status (HR = 1.6, 95% CI 1.2–
2.1; P < 0.001) were independently associated with worse survival.
In patients in whom at least one LN was evaluated, both N1 stage
(HR = 1.6, 95% CI 1.3–2.0; P < 0.001) and positive regional LN
status (HR = 1.6, 95% CI 1.3–2.0; P < 0.001) were also indepen-
dently associated with worse survival.
Discussion
Surgical resection is currently the only means of attempting a cure
in patients with ICC. For resected patients, numerous studies have
demonstrated that metastatic disease to regional LNs is associated
with survival in ICC.4,9,17–19 Similarly, studies in pancreatic, gastric
and colon cancer have demonstrated the importance of LN evalu-
ation to survival.20–22 Despite this knowledge, formal evaluation of
regional LNs in ICC is not widely practised in the USA and no
standard approach to LN evaluation in patients diagnosed with
ICC exists.
Using the SEER registry, a population-based study of national
trends in LN evaluation in patients with ICC during 1988–2007
was conducted. Unlike previous reports on lymphadenectomy
and ICC, the importance of LN status in resected and unresected
patients was investigated. N-stage was known in 48.9% of patients
in the study and histologic regional LN staging was available in
only 13.5%. Of patients treated with major liver resection, just
49.3% underwent histologic evaluation of regional LNs and this
was typically limited to one or two nodes. Lymph node evaluation
was found to be less likely in older patients and in those with
metastatic disease. The number of LNs evaluated and the percent-
age of patients in whom LN evaluation was performed did not
increase over the study period. For patients treated with major
liver resection, no differences were identified between registries.
In Western countries, few studies have investigated the impact
of LN status on the survival of patients with ICC. In 2001, Weber
et al. reported the Memorial Sloan Kettering Cancer Center
(MSKCC) experience with surgical resection in 33 patients diag-
nosed with ICC.23 Three-year survival was 25% in LN-positive
and 59% in node-negative patients. In this study, routine LN
evaluation was advocated to prevent local recurrence. In an
updated analysis of patients treated at MSKCC, Endo et al.4
reported that LN metastasis remained an important predictor of
local recurrence and worse survival in resected patients; however,
the average number of nodes sampled in this study was only 1.9,
which is similar to the number reported in patients in the SEER
registry. Madariaga et al. reported worse survival in node-positive
ICC patients at the University of Pittsburgh.24 In this series of 34
patients, routine lymphadenectomy was performed, but the
number of LNs removed was not reported. In an Italian study by
Ercolani et al., 40% (four of 10) of patients with ICC had LN
metastases at the time of lymphadenectomy.25 Tamandl et al.,
reporting a study of 46 patients from Austria, stated that the
number of LNs retrieved did not predict survival, but an LN
ratio > 0.2 did predict worse survival (HR = 9.8, 95% CI 1.5–43.4;
P = 0.016).17 In this study, a median of six LNs per patient
were retrieved using routine lymphadenectomy.17
Figure 3 Kaplan–Meier survival curves for intrahepatic cholangiocar-
cinoma patients in whom at least one regional lymph node (LN) was
evaluated, by LN status (n = 657)
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Studies in Japan, Korea and China have provided varying per-
spectives on the clinical benefit of lymphadenectomy in ICC. In
2001, Shimada et al., reporting from Japan, compared survival
between no-lymphadenectomy (n = 8) and lymphadenectomy (n
= 41) patients and found no survival difference.19 In the same year,
Tsuji et al. reported that 62% (24 of 39) of patients who under-
went formal lymphadenectomy had positive LNs.26 Only 8% of
the node-positive patients (two of 24) survived beyond 3 years.
Nakagawa et al., in an analysis of 30 patients treated with hepatic
resection and formal lymphadenectomy, reported that an increas-
ing number of positive nodes was associated with worse survival.27
In 2009, Shimada et al. reported a series of 29 patients in which
node-negative patients who underwent LN dissection achieved
survival similar to that of patients who did not undergo lym-
phadenectomy (P = 0.807).28 In this study, lymphadenectomy was
not standardized and was based on clinical suspicion for positive
nodes. In a large series of 429 patients with ICC from China,
positive LN status independently predicted worse survival (HR
1.54, 95% CI 1.0–2.4; P = 0.048).29 Other reports from Asia have
confirmed that positive LNs predict worse survival, but lym-
phadenectomy was not routine in any of these studies and was
typically based on surgeon preference or clinical suspicion.18,29–32
Previous reports utilizing SEER data have confirmed worse sur-
vival in node-positive cholangiocarcinoma.9,33 In a study of gall-
bladder, ECC and intrapancreatic/ampullary bile duct cancers,
Schwarz and Smith determined that the number of positive nodes
and total number of LNs examined were independent predictors
of survival.33 However, the number of LNs evaluated (median = 4,
range: 1–39) was higher than the number evaluated in this study
of ICC and 22% of the ECC patients had 10 or more LNs evalu-
ated.33 In a manuscript which outlined the current AJCC 7th
edition staging system for ICC, Nathan et al. reported worse sur-
vival in LN-positive ICC patients treated with resection.9 In a
small subgroup analysis of 54 N1 M0 patients, patients with three
or more positive LNs had poorer survival than patients with only
one or two positive nodes (HR 3.21, 95% CI 1.23–8.37).9 As we
observed earlier, the findings of Nathan et al.9 were confirmed, but
specific cut-point analyses were not performed given the low
number of LNs sampled, as well as potential study selection and
treatment biases. The inclusion of unresected patients in the
current study reinforces the association of regional nodal status
and worse survival in all patients diagnosed with ICC.
The main limitations of the current study result from the lack of
detailed clinical data in the SEER registry. The SEER database is a
population-based registry that does not collect data on preopera-
tive evaluation, treatment rationale, treatment complications or
comorbidities. Although detailed information is available on the
number and status of regional LNs, this study was unable to
determine why so few patients underwent the removal and histo-
logic evaluation of more than two LNs. We presume this is a result
of surgeon bias. Although adjuvant therapies have not been dem-
onstrated to impact survival in ICC patients, the SEER registry
does not include data on chemotherapy in its database and this,
therefore, could not be factored into the survival analyses. Finally,
the SEER registry has been criticized for substantial missing
data.34 The unavailability of data did complicate the multivariable
analyses. Specifically, 56.8% (n = 2778) and 58.6% (n = 2865) of
data on tumour grade and size, respectively, were missing. Previ-
ous studies of ICC have utilized imputation methods to overcome
problems associated with missing data, but, given the known and
unknown treatment biases associated with lymphadenectomy,
imputation was not appropriate.14 The SEER registry maintains a
high standard in quality and clearly outlines coding algorithms
even in patients with poor documentation. The substantial
number of patients for whom LN status is unknown is unlikely to
represent an artefact of poor quality in the SEER registry, but,
rather, a true reflection of physician biases towards staging and
treatment in ICC.
Conclusions
Analysis of SEER registry data for the period 1988–2007 indicates
that nodal status remains an important prognostic factor in the
survival of patients diagnosed with ICC. Despite undergoing
major liver resection, few patients will undergo the evaluation of
more than one or two LNs. As a result of these limitations to data
on LN status, the clinical benefit of formal lymphadenectomy in
ICC remains unknown. This evidence emphasizes the need to
perform lymphadenectomy as a routine part of surgical resection
in patients with ICC.
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